International Journal of Advanced Biochemistry Research



ISSN Print: 2617-4693
ISSN Online: 2617-4707
IJABR 2024; 8(2): 448-453
www.biochemjournal.com
Received: 25-11-2023
Accepted: 28-12-2023

Hiba H Rasheed
College of Science, University of Tikrit, Tikrit, Iraq

Ali H Obidi
College of Pharmacy, University of Tikrit, Tikrit, Iraq

Taisir K Ibrahim
College of Science, University of Tikrit, Tikrit, Iraq

Firas Shawqi
College of Medicine, University of Tikrit, Tikrit, Iraq

Corresponding Author:
Hiba H Rasheed
College of Science, University of Tikrit, Tikrit, Iraq

Measuring the level of interleukins 27, 30 and some biochemical variables in patients with enlarged prostate

Hiba H Rasheed, Ali H Obidi, Taisir K Ibrahim and Firas Shawqi

DOI: https://doi.org/10.33545/26174693.2024.v8.i2f.598

Abstract
Prostatitis is a swelling and inflammation of the prostate gland. Prostatic inflammation, which may be extremely painful and unpleasant, may contribute to the progression of prostate enlargement and benign prostatic hypertrophy (BPH). The goal of this study was to investigate the impact of cytokines interleukin 27 (IL27) and interleukin 30 (IL30) on prostatitis and enlargement and to consider them as novel criteria. When comparing the efficacy of IL27 and IL30 in patients with prostatitis and patients with enlargement in healthy persons, we discovered a difference. IL27 and IL30 are a surrogate of chronic inflammation in the prostate that differs between individuals with hypertrophy and prostatitis**.** Serum IL27 and IL30 levels are elevated. raised in patients with enlarged prostate, according to the findings. The results showed a substantial rise In comparison to the control group, the group of patients with prostatitis and enlargement had a higher amount of IL27 in their blood. IL30 levels in patients' blood serum. Prostatitis and enlargement were considerably more common than in the control group. (p<0.05). Their influence on a range of indicators, including blood pressure, diabetes, age, smoking, the effect of therapy, the type of therapies used, body mass, the environment, and the relationship with other illnesses, was investigated.

Keywords: IL27, IL30, prostate enlargement, prostatitis, benign prostatic hypertrophy

Introduction
Benign prostatic hyperplasia (BPH) occurs when the prostate and surrounding tissue expand. As a man ages, his prostate passes through two major phases of growth. The first happens throughout puberty when the prostate doubles in size. The second begins at the age of 25 and lasts throughout a man's life. As you age, your prostate gland may grow. BPH occurs when the prostate becomes big enough to create issues [1, 2]. The prostate expands and pushes on the urethra. The wall of the bladder thickens. Over time, the bladder may weaken and lose its capacity to empty. Urine is then held in the bladder [3, 4]. These aberrations are responsible for a large number of BPH-related lower urinary tract symptoms. Age is the most significant risk benign prostatic hyperplasia is a risk factor for BPH, and the clinical symptoms of BPH are strongly linked to an increase in PV produced by advanced age [5]. Given the high incidence of BPH/LUTS in elderly men, as well as the high cost of medication and early detection of individuals at risk for progression events, it is critical to uncover novel risk factors for BPH/LUTS morbidity and progression [6]. BPH can be aggravated by repeated urinary tract infections [7] and bladder stones [8]. It is estimated that 50% of men with histological BPH have moderate to severe lower urinary tract symptoms [9]. Acute urinary retention (inability to empty), necessitating urgent bladder catheterization, is infrequent, with an annual risk of less than 1%; long-term renal insufficiency is unusual. [10, 11] Management recommendations should thus be based on the existence and severity of symptoms. Prostatitis is an inflammatory disease of the glands that make up the prostate that causes a range of complex symptoms including pelvic and lower abdominal discomfort, as well as obstructive and erectile dysfunction [12]. There are four forms of prostatitis: acute bacterial prostatitis (I), chronic bacterial prostatitis (II), chronic prostatitis/chronic pelvic pain syndrome (III), and asymptomatic inflammatory prostatitis. The presence or absence of leukocyte infiltration in prostatic tissues separates type III CP/CPPS between IIIA and IIIB [14]. The prevalence of prostate in urological surgical clinics ranges from 8 to 25%, with Type III CP/CPPS

accounting for 90-95% of all cases [13, 15]. Prostatitis, particularly non-bacterial prostatitis, has a complex aetiology and pathogenic profile. Saponaceousness, immunological diseases, hormones, diet, stress, chemicals, urinary reflux, exosomes, and autonomic nerves have all been associated with prostate cancer. Prostatitis can be treated with antibiotics, pain medicines, alpha-blockers, physiotherapy, prostate massage, and lifestyle modifications. Current prostatitis therapies are heavily influenced by the root cause and severity. Antibiotics combat bacterial infections, pain relievers alleviate discomfort, and alpha blockers relax the muscles surrounding the prostate, improving urine symptoms. Physiotherapy reduces discomfort and enhances muscular function in the pelvic area. [16, 17]. Interleukin (IL)-27 is a cytokine that performs various immune-related tasks [18, 19]. IL27 is made up of two subunits: IL27p28 and Epstein-Barr virus-induced 3 (EBI3), which interact with a heterodimeric membrane sensor made up of IL27R and gp130 [18]. IL27 is a novel cytokine having immunostimulatory and immunosuppressive effects on a wide range of immune cells [20, 21]. Myeloid cells, including monocytes, macrophages, and dendritic cells, are the primary producers of IL30 and IL27. Proinflammatory ILs have been associated with the advancement of BPH in several studies. B cell-derived IL30 was shown to be critical in enhancing CD8 T cell reconstitution in the study.

Materials and Methods

Sample collection*:* From February 2022 to October 2023, sera were collected from 50 benign prostatic hyperplasia and 50 prostatitis patients with 45 controls. From the hospital. The ages of the patients ranged between 32 to 85 years, with an average of (70.61±8.30) years, and a medical history from 0.4 to 11 years. 5 patients had acute urinary retention. The sample was sent to the laboratory so that the blood samples could be separated using a separator to separate the serum from the plasma. It was then preserved in a deep freeze to study the effect of the parameters on the samples.

Determination of IL27 and IL30: Serum IL27 9 (Cat. No. E5520Hu) and serum IL30 (Cat. No. ELK9351) concentration has been determined according to manufacturer instructions using the kit supplied by Bioassay Technology Laboratory (China).

Statistical method: The biochemical data were statistically evaluated using the statistical software tool SPSS17.0. The mean standard deviation (SD) was estimated using ANOVA, and statistical significance was regarded whenever the P value was equal to or less than 0.05.

Results

This study showed a significant increase of IL27 and IL30 in patients with prostate enlargement (20.7±319.4, 61.37±12.47) and prostatitis (23.2±288.6, 53.65±10.04) compared with control (225.9±29.9, 7.29±21.04) (Table 1).

Table 1: Serum concentration of IL27 in the studied groups

Parameters	Control	Prostatitis	Prostate enlargement
IL27 (ng/L)	225.9±29.9	23.2±288.6^	20.7±319.4*
IL30 (ng/L)	7.29±21.04	53.65±10.04^	61.37±12.47*
Data expressed as mean±SD, *^ indicate significant differences at $p<0.05$, *as compared to either control or prostatitis, ^ as compared to the control group.			

In prostate enlargement and prostatitis patients, IL27 has shown a significantly higher level in ages of 30-45 years (415.0±35.4, 265.0±36.6) compared with 46-85 years (348.1±36.9, 235.2±32.9), respectively. In prostatitis patients, IL27 levels were significantly elevated in overweight (378.8±32.1) and obese (270.5±54.2) groups compared to the normal body weight group (233.1±19.5). In prostate enlargement, non-significant differences exist between patients with normal body, overweight, and obese. In prostate enlargement patients, smokers (411.1±31.6) have significantly higher IL27 compared to non-smokers (314.9±34.4), while no differences exist in IL27 lever between smokers (264.2±34.1) versus non-smokers (269.2±33.9) in prostatitis groups. In prostate enlargement and prostatitis, non-significant differences exist between patients with or without compiling diseases. In prostate enlargement and prostatitis, non-significant differences exist between patients dwelling in rural areas compared to those dwelling in urban locations.

In prostate enlargement and prostatitis, patients without genetic link (298.5±27.0, 307.5±24.9) have significantly higher IL27 levels compared to those with genetic link (194.7±24.5, 150.1±29.1), respectively. Hypertension has non-significantly changed the level of IL27 in either group of prostate enlargement or prostatitis. Hyperglycemia has significantly elevated serum IL27 levels in prostate enlargement and prostatitis (341.1±46.9, 255.2±59.9) compared to the normal blood sugar group (290±28.7, 226.3±39.6), respectively. The type of drug selected has no impact on the level of IL27 in either group of prostate enlargement or prostatitis (Table 2).

In prostate enlargement, IL30 has shown a significant increase in the ages of 46-85 years (69.95±14.39) compared with 30-45 years (64.63±12.44). Conversely, in prostatitis, IL30 has shown a significant increase in the ages of 30-45 years (277.80±41.9) compared with 46-85 years (44.07±10.6). In prostate enlargement patients, IL30 levels significantly elevated in the normal body weight group (67.42±18.19) compared to overweight (62.87±11.74) and obese (55.34±8.511) groups. Conversely, IL30 decreased significantly in overweight (51.68±16.33) and obese (50.30±12.6), compared to normal body weight (67.40±13.5) in prostatitis patients. In prostate enlargement patients, smokers (69.63±14.43) have significantly increased IL30 levels compared to non-smokers (59±14.22), while in prostatitis, non-significant differences in IL30 levels exist between non-smokers (50.88±10.82) compared to smokers (59.84±12.97).

Table 2: The serum concentration of IL27 relative to their demographic parameters in patient groups

Demographic Parameters		Prostatitis	Prostate enlargement
Age (years)	30 - 45	265.0±36.6a	415.0±35.4 a
	46-85	235.2±32.9b	348.1±36.9 b
BMI	Normal	233.1±19.5a	383.1±38.6 a
	Over Weight	378.8±32.1 b	378.8±32.1 a
	Obese	270.5±54.2b	356.0±21.0 a
Smoking status	Positive	264.2±34.1	411.1±31.6
	Negative	269.2±33.9	314.9±34.4
Diseases status	Positive	259.6±20.3	281.2±25.3
	Negative	264.3±24.1	284.7±24.3
Geography	Rural	249.3±95.2a	375.5±307.7a
	Urban	235.0±42.8a	383.5±212.8a
Genetic status	Positive	150.1±29.1a	194.7±24.5a
	Negative	307.5±24.9b	298.5±27.0b
Hypertension	Positive	58.9±283.0	46.2±324.0
	Negative	278±56.8	47.9±341.4
Hyperglycemia	Positive	59.9±255.2a	46.9±341.4a
	Negative	226.3±39.6b	290±28.7b
Therapy Current	Urimax capsule	----	41.5±278.3
	Xradal tablet	----	253.1±40.7
	Prostacalm capsule	385.0±39.2	----
	Prostanil tablets	303.6±21.63	----

Data expressed as mean±SD, different letters indicate significant differences at $p<0.05$ within the same group, Prostanil=Finasteride, Prostcalm=a combination of natural plant extracts with organic and mineral antioxidants, Xradal =alfuzosin, Urimax= tamsulosin

In prostate enlargement and prostatitis, the compiling diseases (67.64±14.31, 120.8±22.2) have significantly increased IL30 levels compared to their absence (59.72±14.57, 58.69±18.87), respectively. In prostate enlargement, non-significant differences exist in IL30 levels between patients dwelling in rural areas (63.52±27.07) and urban areas (63.01±20.85), while in prostatitis, patients living in urban (55.79±19.94) areas have significantly higher IL30 levels compared to those dwelling in rural locations (47.93±19.48). In prostate enlargement and prostatitis, patients without genetic link (64.86±16.96, 62.92±16.72) have significantly higher IL30 levels compared to those with genetic link (24.33±6.69, 25.18±8.81), respectively.

Hypertension has significantly decreased the level of IL30 in either group of prostate enlargement (41.61±18.1) or prostatitis (49.99±13.61) compared to non-hypertensive (71.81±19.69, 58.54±13.46), respectively. Hyperglycemia has significantly elevated serum IL30 levels in prostate enlargement and prostatitis (55.92±16.65, 52.38±17.73) compared to the normal blood sugar group (21.78±7.06, 16.45±6.38), respectively. The type of drug selected has no impact on the level of IL27 in either group of prostate enlargement or prostatitis (Table 3).

Table 3: Serum concentration of IL30 relative to their demographic parameters in patient groups

Demographic Parameters		Prostatitis	Prostate enlargement
Age (years)	30 - 45	277.80±41.90a	64.63±12.44b
	46-85	44.07±10.60b	69.95±14.39a
BMI	Normal	67.40±13.50 a	67.42±18.19 a
	Over Weight	51.68±16.33b	62.87±11.74 a
	Obese	50.30±12.60 b	55.34±8.511 b
Smoking status	Positive	50.88±10.82a	69.63±14.43a
	Negative	59.84±12.97a	59.00±14.22b
Diseases status	Positive	120.80±22.20a	67.64±14.31a
	Negative	58.69±18.87b	59.72±14.57b
Geography	Rural	47.93±19.48a	63.52±27.07a
	Urban	55.79±19.94b	63.01±20.85a
Genetic status	Positive	25.18±8.81a	24.33±6.69a
	Negative	62.92±16.72b	64.86±16.96b
Hypertension	Positive	13.61±49.99a	18.10 61.±41a
	Negative	13.46±58.54b	19.69±71.81b
Hyperglycemia	Positive	17.73±52.38 a	16.65±55.92 a
	Negative	6.38±16.45b	7.06±21.78b
Therapy Current	Urimax capsule	----	63.32±15.86a
	Xradal tablet	----	59.65±13.74a
	Prostacalm capsule	57.04±18.56a	----
	Prostanil tablets	59.89±18.31a	----

Data expressed as mean±SD, different letters indicate significant differences at p<0.05 within the same group, Prostanil=Finasteride, Prostcalm=a combination of natural plant extracts with organic and mineral antioxidants, Xradal =alfuzosin, Urimax= tamsulosin

Discussion

The development of biomarkers detectable in blood samples in BPH patients may be effective in differentiating those prevalent prostate disorders as well as identifying unique therapy options. Inflammation and endothelial activation patterns appear to provide a biological connection between pathophysiology and clinical symptoms of prostatic illness, as well as predict the start and progression of both BPH and prostate cancer. Furthermore, deregulation of the immune response in BPH may arise due to increased expression of pro-inflammatory IL27- which increases the synthesis of stromal growth factor [24]. According to these ideas, we discovered that IL27 was elevated systemically in BPH patients. This finding verifies the role of IL27 in the development of BPH and suggests that it may be useful in distinguishing prostatic inflammatory hypertrophy from normal gland tissue. IL27 levels were found to be higher in patients with prostatitis and hyperplasia compared to controls, indicating that IL 27 levels rise with disease and fall with control, which is consistent with the fact that IL, or cytokines, has a strong relationship with the presence of infections. When we looked at the effectiveness of IL 27 in patients with prostatic hypertrophy and prostatitis based on age, we discovered that there was no difference in IL 27 in patients with prostatic hypertrophy between 30-45 years old and patients over 45 years old. 45-85 years, while those who have There was a modest rise in prostatitis in the 30-45 age group compared to the 46-85 age group, indicating that age does not impact IL activity. Longer life expectancy will make it a significant public health problem in the near future [25]. Research found that nocturnal urination related to prostate inflammation and enlargement rises with age, but nocturnal bladder capacity declines [26]. The effect of IL 27 on body mass index, which Can forecast prostate volume in middle-aged men, is still debatable. According to Yang *et al*. [27], the activity of IL 27 rises in individuals with prostate enlargement of normal weight and those with high weight as compared to those with extreme obesity. Insulin resistance, accompanied by secondary hyperinsulinemia, has two key consequences: Increased sympathetic nervous system activity is associated with obesity-related inflammation. These variables have been linked to prostate development and hypertrophy [28-32]. The effect of IL 27 on individuals with prostatic hyperplasia was also investigated in terms of smoking since we discovered a rise in the percentage of smokers as compared to non-smokers. We found no difference between smokers and non-smokers when exposed to different exogenous important smoke Long-term exposure to agents such as chemicals in the workplace can have an impact on metabolism, both physiological and biochemical [33]. A study was conducted in a densely populated north Indian region to investigate the link of various forms of tobacco use with inflammation in prostate cancer patients by measuring blood IL-pro-inflammatory levels. Our data suggest that tobacco chewing and smoking may contribute significantly to inflammation [34]. According to the findings, there is an increase in the effectiveness of IL 27 in patients with prostatic enlargement who do not have a history of illness compared to patients who do, and also a significant increase in patients with prostatitis who do not have a family history of the disease compared to those who do, indicating. There is a considerable difference, however, there is no difference between people with inflammation who have other disorders and those who do not. Patients with prostate enlargement without genetic factors have an increase compared to patients with genetic factors, while patients with prostatitis without genetic factors have an increase compared to patients without genetic factors. We found no difference between patients with prostatic enlargement and blood pressure and those who did not have blood pressure [34]. In terms of patients with prostatitis who had blood pressure, we found no difference between those who had blood pressure and those who did not have blood pressure. effected IL 27 in patients with prostate enlargement with high blood sugar increase significantly more than without blood sugar, and showed the affected IL 27 in patients with prostatitis with high blood sugar increase significantly more than without blood sugar, the current knowledge is consistent with previous findings [35, 36]. This was consistent with our findings, which found a favourable link between diabetes treatment duration and prostate volume. Indeed, type 2 diabetes and benign prostatic hyperplasia appear to share epidemiological characteristics, which may be connected to age and food [37]. Barnard *et al* [38] linked lower insulin sensitivity to decreased development of prostatic epithelial stem cells. The results indicated that the affected IL 27 in patients with prostate enlargement who used kind drag urimxe did not differ significantly from those who used kind drag xradal in a previous trial, despite the fact that men with chronic prostatitis regularly get anti-inflammatory and antibacterial medication; nevertheless, they discovered that leukocyte and bacterial counts, as defined by them, do not correspond with the severity of symptoms [39]. While people with prostatitis who used kind drag prost calm exhibited a substantial rise when compared to individuals who used prostalin.

Myeloid cells, including monocytes, macrophages, and dendritic cells, are the principal sources of IL30 [17]. Microglia and astrocytes in the central nervous system, alveolar and interstitial macrophages in lung tissue, and Kupffer cells in the liver may all produce IL30 [40, 41, 42]. A vast body of data shows that IL30 plays an important role in the shift from hormone and infection reliance. We discovered that IL30 was elevated systemically in BPH patients compared to controls. This study supports IL30's significance in the development of BPH and implies that it may be effective in separating prostatic inflammatory hypertrophy from normal gland tissue. The results showed that IL 30 levels were higher in patients with prostatitis and hyperplasia compared to controls, indicating that IL 30 levels rise with disease and fall with control, which is consistent with the fact that IL, cytokines, have a strong relationship with the presence of infections. When studying the effectiveness of IL30 in patients with prostatic hypertrophy and prostatitis, we discovered that there is a slight difference in the level of IL 27 in patients suffering from prostate enlargement compared to patients in the age group of 45-85 years, while in those with prostatitis, there was an increase in the age group of 45-85 years. The age group is 30-45 years compared to 46-85 years, indicating that ageing influences IL activity. IL 30's influence on body mass. Based on the findings in the tables above, we infer that the activity of IL 30 rises in patients with prostatic enlargement. While increasing in people with prostatitis as compared to normal and obese bodies. The smoking impact of IL 30 on patients with prostatic hypertrophy was also investigated. We did not find any difference in the percentage of smokers vs non-smokers. In terms of

prostatitis patients, we found that nonsmokers outnumbered smokers. Much research has revealed that cigarette smoking, alcoholic drinking, and betel quid chewing have a synergistic impact on the carcinogenesis of oral cavity mucosa. In a study identical to ours, the routes of IL-18 generation that were investigated are extensively established, although their apparent method of action in prostatitis patients is less so. IL-18's biological activities are carried out through its capacity to boost innate immunity as well as Th1 and Th2-mediated responses [43]. The findings revealed an increase in the efficacy of IL 30 in patients with prostatic enlargement who did not have a medical history compared to patients who did, as well as a substantial rise in prostatitis patients who did not have a medical history. Those with no family history of the condition were compared to those who had a family history of the disease. This suggests that the efficacy of IL rises in people with no history of the disease and diminishes in those with a history of the condition. According to the data, hypertrophic patients who reside in the countryside outperformed individuals with enlarged prostate. We found no difference in IL 30 activity between patients suffering from prostatitis in the city and patients suffering from prostatitis in the rural. The impact of IL 30 on the existence of other illnesses was studied, and it was discovered that there is no difference in patients with prostate enlargement who have disorders compared to individuals who do not have other diseases. We saw an increase in inflammation in individuals with other disorders compared to those who did not have other diseases**.** We found a somewhat significant rise in individuals with prostate enlargement who did not have high blood pressure compared to those with high blood pressure. In terms of patients with prostatitis who have high blood pressure, we found no difference between those who had high blood pressure and those who did not. IL 30 levels are significantly higher in prostatic hypertrophy individuals with high blood sugar levels. with no blood sugar, and the effect of IL 30 in prostatitis patients with high blood sugar shows a significant increase when compared to those without blood sugar. Previous research has suggested that IL30 may have a variety of functions in various inflammatory disorders. The role of IL30 in diabetes differs from that in other autoimmune diseases or allergic infections. According to Min *et al*., IL30 is necessary for the development of type 1 diabetes [45]. The results demonstrated that IL 30 did not affect patients with prostate enlargement who used kind drag urimxe when compared to those who used kind drag xradal, and patients with prostatitis who used kind drag prost calm when compared to patients who used prostaline.

Conclusion

These findings link IL27,30 to human prostate pathology, and this model provides a versatile platform for studying the molecular basis of inflammation-related prostate diseases associated with episodic or chronic IL27,30 levels. Regarding BPH, inflammation may be taken into consideration in the optimal therapy selection as if detected individuals should have a symptomatic positive improvement by adding anti-inflammatory medications to regular treatments. Changes in inflammation and endothelial activation-specific indicators identified in BPH patients may not be regarded as useful in differentiating those prostate illnesses.

References

1. Walsh PC. Campbell's Urology, 8th ed. Saunders, Philadelphia. 2002;2566:1245-1249.
2. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, *et al*. The prevalence of prostatism: a population-based survey of urinary symptoms. The Journal of urology. 1993 Jul 1;150(1):85-89.
3. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE. Natural history of prostatism: longitudinal changes in voiding symptoms in community-dwelling men. The Journal of urology. 1996 Feb;155(2):595-600.
4. Wei JT, Schottenfeld D, Cooper K, Taylor JM, Faerber GJ, Velarde MA, *et al*. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate, and bothersomeness. The Journal of urology. 2001 May;165(5):1521-1525.
5. McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr GL, Dixon CM, Kusek JW, *et al*. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine. 2003 Dec 18;349(25):2387-2398.
6. Emberton M, Andriole GL, De La Rosette J, Djavan B, Hoefner K, Navarrete RV, *et al*. Benign prostatic hyperplasia: A progressive disease of aging men. Urology. 2003 Feb 1;61(2):267-273.
7. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Disorders of the Prostate. 2004 Jul 8:12-32.
8. Sugimura Y. Epidemiology and natural history of benign prostatic hyperplasia. Nihon rinsho. Japanese journal of clinical medicine. 2002 Dec 1;60:318-21.
9. American Urological Association. Guideline on the management of benign prostatic hyperplasia (BPH). http://www.auanet.org/guidelines/bph.cfm. Accessed September 19, 2007.
10. McConnell JD, Roehrborn CG, Bautista OM, Andriole Jr GL, Dixon CM, Kusek JW, *et al*. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine. 2003 Dec 18;349(25):2387-2398.
11. Breser ML, Salazar FC, Rivero VE, Motrich RD. Immunological mechanisms underlying chronic pelvic pain and prostate inflammation in chronic pelvic pain syndrome. Frontiers in immunology; c2017. p. 898.
12. Krieger JN, Nyberg Jr L, Nickel JC. NIH consensus definition and classification of prostatitis. Jama. 1999 Jul 21;282(3):236-237.
13. Habermacher GM, Chason JT, Schaeffer AJ. Prostatitis/chronic pelvic pain syndrome. Annu. Rev. Med. 2006 Feb 18;57:195-206.
14. Krieger JN, Lee SW, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J antimicrobial Agents (2008) 31 Suppl 1(Suppl 1):S85-90. doi: 10.1016/j.ijantimicag.2007.08.028.
15. Franco JV, Turk T, Jung JH, Xiao YT, Iakhno S, Tirapegui FI, *et al*. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database of Systematic Reviews. 2019(10).
16. Franco JV, Turk T, Jung JH, Xiao YT, Iakhno S, Tirapegui FI, *et al*. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain

syndrome: a Cochrane systematic review. BJU international. 2020 Apr;125(4):490-6.
17. Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, *et al*. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002 Jun 1;16(6):779-790.
18. Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annual review of immunology. 2015 Mar 21;33:417-443.
19. Lucas S, Ghilardi N, Li J, de Sauvage FJ. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and-independent mechanisms. Proceedings of the National Academy of Sciences. 2003 Dec 9;100(25):15047-15052.
20. Petes C, Odoardi N, Plater SM, Martin NL, Gee K. IL-27 amplifies cytokine responses to Gram-negative bacterial products and *Salmonella typhimurium* infection. Scientific Reports. 2018 Sep 12;8(1):13704.
21. Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annual review of immunology. 2015 Mar 21;33:417-443.
22. Ayasoufi K, Zwick DB, Fan R, Hasgur S, Nicosia M, Gorbacheva V, *et al*. Interleukin-27 promotes CD8+ T cell reconstitution following antibody-mediated lymphoablation. JCI insight. 2019 Apr 4;4(7).
23. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European urology. 2007 May 1;51(5):1202-1216.
24. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, *et al*. Antiproliferative activity of IL-27 on melanoma. The Journal of Immunology. 2008 May 15;180(10):6527-6535.
25. Michel MC, Schneider T, Krege S, Goepel M. Does gender or age affect the efficacy and safety of tolterodine? The Journal of urology. 2002 Sep;168(3):1027-1031.
26. Yang HJ, Doo SW, Yang WJ, Song YS. Which obesity index best correlates with prostate volume, prostate-specific antigen, and lower urinary tract symptoms? Urology. 2012 Jul 1;80(1):187-190.
27. Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. European urology. 2001 Feb 1;39(2):151-158.
28. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. European urology. 2008 Dec 1;54(6):1379-1384.
29. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, *et al*. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol;60(1):106-17(2011). pmid:21497433.
30. Sarma AV, Parsons JK, McVary K, Wei JT. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms—what do we know?. The Journal of urology. 2009 Dec 1;182(6):S32-S37.
31. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). International journal of obesity. 2005 Mar;29(3):310-316.
32. Lee IP, Suzuki K. Induction of aryl hydrocarbon hydroxylase activity in the rat prostate glands by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin. Journal of Pharmacology and Experimental Therapeutics. 1980 Dec 1;215(3):601-605.
33. Lee IP, Suzuki K, Lee SD, Dixon RL. Aryl hydrocarbon hydroxylase induction in rat lung, liver, and male reproductive organs following inhalation exposure to diesel emission. Toxicology and Applied Pharmacology. 1980 Jan 1;52(1):181-184.
34. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia. Prostate cancer and prostatic diseases. 1998 Mar;1(3):157-162.
35. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. European urology. 2007 Jan 1;51(1):199-206.
36. Gades NM, Jacobson DJ, Girman CJ, Roberts RO, Lieber MM, Jacobsen SJ. Prevalence of conditions potentially associated with lower urinary tract symptoms in men. BJU international. 2005 Mar;95(4):549-553.
37. Barnard RJ, Kobayashi N, Aronson WJ. Effect of diet and exercise intervention on the growth of prostate epithelial cells. Prostate Cancer and Prostatic Diseases. 2008 Dec;11(4):362-366.
38. Schaeffer AJ, Knauss JS, Landis JR, Propert KJ, Alexander RB, Litwin MS, *et al*. Leukocyte and bacterial counts do not correlate with the severity of symptoms in men with chronic prostatitis: The National Institutes of Health Chronic Prostatitis Cohort Study. The Journal of urology. 2002 Sep;168(3):1048-1053.
39. Sénécal V, Deblois G, Beauseigle D, Schneider R, Brandenburg J, Newcombe J, *et al*. Production of IL-27 in multiple sclerosis lesions by astrocytes and myeloid cells: modulation of local immune responses. Glia. 2016 Apr;64(4):553-569.
40. Mathie SA, Dixon KL, Walker SA, Tyrrell V, Mondhe M, O'Donnell VB, *et al*. Alveolar macrophages are sentinels of murine pulmonary homeostasis following inhaled antigen challenge. Allergy. 2015 Jan;70(1):80-89.
41. Bartkowiak T, Jaiswal AR, Ager CR, Chin R, Chen CH, Budhani P, *et al*. Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27-dependent pathway. Clinical Cancer Research. 2018 Mar 1;24(5):1138-1151.
42. Castellsagué X, Quintana MJ, Martínez MC, Nieto A, Sánchez MJ, Juan A, *et al*. The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. International journal of cancer. 2004 Feb 20;108(5):741-749.
43. Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Cancer research. 2000 Sep 1;60(17):4838-4844.
44. Min B, Kim D, Feige MJ. IL-30(IL-27A): A familiar stranger in immunity, inflammation, and cancer. Experimental & Molecular Medicine. 2021 May;53(5):823-834.